| scholarly article | Q13442814 |
| P2093 | author name string | A. Nisalak | |
| D. S. Burke | |||
| S. C. Kliks | |||
| S. Nimmanitya | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| dengue hemorrhagic fever | Q18554268 | ||
| maternally-acquired immunity | Q71159167 | ||
| Dengue virus | Q476209 | ||
| P304 | page(s) | 411-9 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | American Journal of Tropical Medicine and Hygiene | Q15766943 |
| P1476 | title | Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants | |
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | |||
| P478 | volume | 38 |
| Q56876075 | 10 The Emergence of Dengue: Past Present and Future |
| Q27490166 | A Prospective Nested Case-Control Study of Dengue in Infants: Rethinking and Refining the Antibody-Dependent Enhancement Dengue Hemorrhagic Fever Model |
| Q27486406 | A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus |
| Q40475448 | A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. |
| Q36849774 | A dengue DNA vaccine formulated with Vaxfectin®is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits |
| Q47156413 | A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus |
| Q37679389 | A systematic approach to virus-virus interactions. |
| Q92334511 | A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease |
| Q99564799 | A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity |
| Q35806060 | A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model |
| Q27480826 | Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes |
| Q27477784 | Advances in dengue diagnosis |
| Q27481478 | An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling Mice |
| Q24606493 | An in-depth analysis of original antigenic sin in dengue virus infection |
| Q37987131 | Animal Models of Dengue Virus Infection |
| Q27490452 | Antibodies Induced by Dengue Virus Type 1 and 2 Envelope Domain III Recombinant Proteins in Monkeys Neutralize Strains with Different Genotypes |
| Q34202698 | Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2 |
| Q36931818 | Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo |
| Q34810301 | Antibodies, viruses and vaccines |
| Q39002738 | Antibody recognition of the dengue virus proteome and implications for development of vaccines |
| Q28827957 | Antibody responses to Zika virus infections in flavivirus-endemic environments |
| Q25708015 | Antibody-Dependent Enhancement of Dengue Virus Infection in Primary Human Macrophages; Balancing Higher Fusion against Antiviral Responses |
| Q36628520 | Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy |
| Q40673105 | Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants. |
| Q47592202 | Antibody-dependent enhancement of severe dengue disease in humans |
| Q34999617 | Antibody-mediated neutralization of flaviviruses: a reductionist view |
| Q57008751 | Arboviruses and pregnancy: maternal, fetal, and neonatal effects |
| Q36487320 | Association between magnitude of the virus-specific plasmablast response and disease severity in dengue patients |
| Q42991886 | Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis |
| Q55277816 | Biochemistry and Molecular Biology of Flaviviruses. |
| Q29365355 | Biologic Evidence Required for Zika Disease Enhancement by Dengue Antibodies |
| Q58792953 | Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies |
| Q34289194 | CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice |
| Q27491351 | Clinical and Virological Features of Dengue in Vietnamese Infants |
| Q27484661 | Comparison of Plaque- and Flow Cytometry-Based Methods for Measuring Dengue Virus Neutralization |
| Q27485131 | Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner |
| Q27490423 | Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus |
| Q35758626 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies |
| Q64101350 | Concurrent infections of dengue virus serotypes in Bali, Indonesia |
| Q91807708 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention |
| Q38016235 | Controversies in dengue pathogenesis |
| Q37907783 | Critical issues in dengue vaccine development |
| Q90358753 | Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population |
| Q27477511 | Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok |
| Q40316344 | Decay and persistence of maternal dengue antibodies among infants in Bangkok |
| Q27485469 | Decision Tree Algorithms Predict the Diagnosis and Outcome of Dengue Fever in the Early Phase of Illness |
| Q27654848 | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity |
| Q36883189 | Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever |
| Q33425879 | Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection |
| Q34722528 | Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity |
| Q29619772 | Dengue |
| Q85327578 | Dengue |
| Q91271250 | Dengue |
| Q96163477 | Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-Dependent Enhancement (ADE): A Perspective |
| Q27489549 | Dengue Hemorrhagic Fever in Infants: Research Opportunities Ignored |
| Q40133947 | Dengue Human Infection Models to Advance Dengue Vaccine Development |
| Q59359154 | Dengue Infection Spectrum in Guangzhou: A Cross-Sectional Seroepidemiology Study among Community Residents between 2013 and 2015 |
| Q24737469 | Dengue Virus Antibodies Enhance Zika Virus Infection |
| Q61795493 | Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy |
| Q35641205 | Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. |
| Q99574588 | Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models |
| Q29620093 | Dengue and dengue haemorrhagic fever |
| Q37778918 | Dengue conundrums |
| Q35625026 | Dengue epidemiology: virus epidemiology, ecology, and emergence |
| Q38386336 | Dengue human infection models to advance dengue vaccine development |
| Q33340800 | Dengue in New Caledonia. Study of 68 pediatric cases |
| Q27489388 | Dengue in Vietnamese Infants—Results of Infection‐Enhancement Assays Correlate with Age‐Related Disease Epidemiology, and Cellular Immune Responses Correlate with Disease Severity |
| Q33389194 | Dengue in infants: an overview |
| Q92397008 | Dengue infection and advances in dengue vaccines for children |
| Q42996339 | Dengue infection. |
| Q34663993 | Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas |
| Q35183803 | Dengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors |
| Q34019949 | Dengue viral infections; pathogenesis and epidemiology |
| Q34118200 | Dengue virus |
| Q31110897 | Dengue virus NS1 enhances viral replication and pro-inflammatory cytokine production in human dendritic cells |
| Q28353949 | Dengue virus antibodies enhance Zika virus infection |
| Q36286276 | Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus |
| Q40300465 | Dengue virus infection in renal allograft recipients: a case series during 2010 outbreak |
| Q35659085 | Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice |
| Q40644721 | Dengue virus infection: Epidemiology, pathogenesis, clinical presentation, diagnosis, and prevention |
| Q35121606 | Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants |
| Q28278881 | Dengue virus life cycle: viral and host factors modulating infectivity |
| Q34746693 | Dengue virus neutralization in cells expressing Fc gamma receptors |
| Q56396121 | Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate |
| Q24645380 | Dengue virus pathogenesis: an integrated view |
| Q37694855 | Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice |
| Q27485093 | Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity |
| Q35294150 | Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera |
| Q36926525 | Dengue viruses cluster antigenically but not as discrete serotypes |
| Q35276730 | Dengue--quo tu et quo vadis? |
| Q33435669 | Dengue: A Clinicohaematological Profile |
| Q28298464 | Dengue: a continuing global threat |
| Q35775955 | Dengue: an arthropod-borne disease of global importance |
| Q29618270 | Dengue: an update |
| Q24609884 | Dengue: defining protective versus pathologic immunity |
| Q28729764 | Dengue: knowledge gaps, unmet needs, and research priorities |
| Q64099613 | Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines |
| Q37115807 | Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? |
| Q40561635 | Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus |
| Q39038294 | Do escape mutants explain rapid increases in dengue case-fatality rates within epidemics? |
| Q35842365 | Dominant Cross-Reactive B Cell Response during Secondary Acute Dengue Virus Infection in Humans |
| Q27472667 | Dynamic effects of antibody-dependent enhancement on the fitness of viruses |
| Q35895444 | Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity |
| Q38887040 | Early dengue virus interactions: the role of dendritic cells during infection |
| Q34875673 | Economic value of dengue vaccine in Thailand |
| Q34422058 | Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial |
| Q41995967 | Enhancement of Zika Infection by Dengue-Specific Antibodies Does Not Alter the Production of Interleukin 6 in FcγRII-Expressing K562 Cells |
| Q29196526 | Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity |
| Q34189997 | Enterovirus 71 Infection of Monocytes with Antibody-Dependent Enhancement |
| Q21131163 | Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections |
| Q40125629 | Epidemiology and characteristics of the dengue outbreak in Guangdong, Southern China, in 2014. |
| Q33428741 | Epidemiology of Dengue Among Children Aged < 18 Months-Puerto Rico, 1999-2011. |
| Q35866928 | Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics |
| Q39448996 | Evaluation of the MRL diagnostics dengue fever virus IgM capture ELISA and the PanBio Rapid Immunochromatographic Test for diagnosis of dengue fever in Jamaica. |
| Q40576046 | Facilitation of cell adhesion by immobilized dengue viral nonstructural protein 1 (NS1): arginine-glycine-aspartic acid structural mimicry within the dengue viral NS1 antigen |
| Q40630801 | Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever |
| Q26783175 | Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases |
| Q24289308 | Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health |
| Q31156754 | First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies |
| Q30857727 | Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus |
| Q35140466 | Formation of infectious dengue virus-antibody immune complex in vivo in marmosets (Callithrix jacchus) after passive transfer of anti-dengue virus monoclonal antibodies and infection with dengue virus |
| Q34563624 | Frequent in-migration and highly focal transmission of dengue viruses among children in Kamphaeng Phet, Thailand |
| Q36878970 | Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. |
| Q34639559 | Genetic variants of MICB and PLCE1 and associations with non-severe dengue |
| Q51733798 | Genotype-specific and cross-reactive neutralizing antibodies induced by dengue virus infection: detection of antibodies with different levels of neutralizing activities against homologous and heterologous genotypes of dengue virus type 2 in common m |
| Q39668466 | Genotype-specific neutralization and protection by antibodies against dengue virus type 3. |
| Q39519169 | Geographical heterogeneity of dengue transmission in two villages in southern Vietnam |
| Q34566234 | Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production |
| Q26314609 | Human antibody response to dengue virus: implications for dengue vaccine design |
| Q47558315 | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity |
| Q33679954 | Hypoxia enhances antibody-dependent dengue virus infection |
| Q24311739 | IFITM proteins restrict antibody-dependent enhancement of dengue virus infection |
| Q33438726 | IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity |
| Q27490592 | Immature Dengue Virus: A Veiled Pathogen? |
| Q35179653 | Immature dengue virus is infectious in human immature dendritic cells via interaction with the receptor molecule DC-SIGN. |
| Q37827145 | Immune Response to Dengue Virus and Prospects for a Vaccine |
| Q33924674 | Immune correlates for dengue vaccine development |
| Q38652971 | Immune correlates of protection for dengue: State of the art and research agenda |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q34165624 | Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. |
| Q40334688 | Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. |
| Q51131051 | Immunological serotype interactions and their effect on the epidemiological pattern of dengue |
| Q35613349 | Immunology and immunopathogenesis of dengue disease |
| Q38631747 | In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants. |
| Q41935971 | Incidence and risk factors for Dengue virus (DENV) infection in the first 2 years of life in a Brazilian prospective birth cohort |
| Q39495783 | Induced autophagy reduces virus output in dengue infected monocytic cells |
| Q40307795 | Infection and activation of human peripheral blood monocytes by dengue viruses through the mechanism of antibody-dependent enhancement. |
| Q36510607 | Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical |
| Q34671059 | Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes |
| Q33394239 | Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status |
| Q100694566 | Learning from the past: development of safe and effective COVID-19 vaccines |
| Q27315772 | Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification |
| Q35133990 | Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection |
| Q37578785 | Low-affinity Fcgamma receptors, autoimmunity and infection |
| Q28236244 | Manipulation of cell surface macromolecules by flaviviruses |
| Q39329367 | Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement |
| Q33430984 | Maternal Antibody-Mediated Disease Enhancement in Type I Interferon-Deficient Mice Leads to Lethal Disease Associated with Liver Damage |
| Q35097469 | Maternal antibody and viral factors in the pathogenesis of dengue virus in infants |
| Q39348200 | Maternally transferred neutralising dengue antibodies in Thai infants: a pilot study |
| Q34306877 | Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop |
| Q54217627 | Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection |
| Q38989101 | Molecular determinants of dengue virus 2 envelope protein important for virus entry in FcγRIIA-mediated antibody-dependent enhancement of infection |
| Q29587283 | Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate |
| Q36572061 | Molecular epidemiological and virological study of dengue virus infections in Guangzhou, China, during 2001–2010 |
| Q38285330 | Molecular epidemiology of autochthonous dengue virus strains circulating in Mexico |
| Q27488337 | Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection |
| Q40499634 | Monoclonal antibody analysis of porcine reproductive and respiratory syndrome virus epitopes associated with antibody-dependent enhancement and neutralization of virus infection |
| Q24684689 | Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention |
| Q24276139 | Mouse models of dengue virus infection for vaccine testing |
| Q27010151 | Mouse models to study dengue virus immunology and pathogenesis |
| Q61804630 | NK Cells Activated through Antibody-Dependent Cell Cytotoxicity and Armed with Degranulation/IFN-γ Production Suppress Antibody-dependent Enhancement of Dengue Viral Infection |
| Q24194181 | NS1 antigen detecting assays for diagnosing acute dengue infection in people living in or returning from endemic countries |
| Q29618172 | Neutralization and antibody-dependent enhancement of dengue viruses |
| Q37721304 | Neutralizing Antibody Response and Efficacy of Novel Recombinant Tetravalent Dengue DNA Vaccine Comprising Envelope Domain III in Mice |
| Q39810460 | Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. |
| Q36498207 | Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q38098308 | New vaccines for neglected parasitic diseases and dengue |
| Q37851212 | Partial maturation: an immune-evasion strategy of dengue virus? |
| Q34420281 | Pathocenosis: a holistic approach to disease ecology |
| Q27860978 | Pathogenesis of dengue: challenges to molecular biology |
| Q62485258 | Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: A microcephaly case-control study in an area of high dengue endemicity in Brazil |
| Q37033074 | Placental Transfer of Dengue Virus (DENV)-Specific Antibodies and Kinetics of DENV Infection-Enhancing Activity in Brazilian Infants |
| Q93133846 | Postnatal Zika virus infection of nonhuman primate infants born to mothers infected with homologous Brazilian Zika virus |
| Q55338916 | Potent Neutralization Ability of a Human Monoclonal Antibody Against Serotype 1 Dengue Virus. |
| Q34750747 | Prevalence and incidence of dengue virus and antibody placental transfer during late pregnancy in central Brazil |
| Q27485010 | Primary Human Splenic Macrophages, but Not T or B Cells, Are the Principal Target Cells for Dengue Virus Infection In Vitro |
| Q40297063 | Profile of circulating levels of IL-1Ra, CXCL10/IP-10, CCL4/MIP-1β and CCL2/MCP-1 in dengue fever and parvovirosis |
| Q30235612 | Prospects for a Zika Virus Vaccine |
| Q29619608 | Prospects for a dengue virus vaccine |
| Q28550953 | Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection |
| Q40248409 | Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus |
| Q39434858 | Protection from Secondary Dengue Virus Infection in a Mouse Model Reveals the Role of Serotype Cross-Reactive B and T Cells |
| Q64252486 | Protein Disulfide Isomerase Inhibitor Suppresses Viral Replication and Production during Antibody-Dependent Enhancement of Dengue Virus Infection in Human Monocytic Cells |
| Q59055979 | Reconstruction of antibody dynamics and infection histories to evaluate dengue risk |
| Q36060983 | Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice |
| Q36234359 | Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection |
| Q38000432 | Research advances in plant-made flavivirus antigens |
| Q40708897 | Restriction enzyme analysis of American region dengue viruses |
| Q27022905 | Return of epidemic dengue in the United States: implications for the public health practitioner |
| Q24655655 | Role of dendritic cells in antibody-dependent enhancement of dengue virus infection |
| Q35855216 | Screening Analogs of β-OG Pocket Binder as Fusion Inhibitor of Dengue Virus 2. |
| Q38087545 | Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection |
| Q27481677 | Secreted NS1 of Dengue Virus Attaches to the Surface of Cells via Interactions with Heparan Sulfate and Chondroitin Sulfate E |
| Q54986343 | Seropositivity of dengue antibodies during pregnancy. |
| Q23925011 | Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host |
| Q39264890 | Signaling by Antibodies: Recent Progress |
| Q33709817 | Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control |
| Q37812659 | Strategies for the plant‐based expression of dengue subunit vaccines |
| Q27678419 | Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity |
| Q27488364 | Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development |
| Q48163643 | Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice |
| Q39576880 | Substitution of the precursor peptide prevents anti-prM antibody-mediated antibody-dependent enhancement of dengue virus infection |
| Q33414560 | Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice |
| Q21144516 | Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse |
| Q56916580 | The Battle between Infection and Host Immune Responses of Dengue Virus and Its Implication in Dengue Disease Pathogenesis |
| Q26700056 | The Cellular Bases of Antibody Responses during Dengue Virus Infection |
| Q26995782 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response |
| Q63246530 | The Conserved Molecular Determinants of Virulence in Dengue Virus |
| Q37987124 | The Human Antibody Response to Dengue Virus Infection |
| Q35880666 | The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice |
| Q39088502 | The Role and Function of Fcγ Receptors on Myeloid Cells |
| Q35594746 | The burden of dengue and chikungunya worldwide: implications for the southern United States and California |
| Q28250383 | The complexity of antibody-dependent enhancement of dengue virus infection |
| Q26314683 | The dengue vaccine pipeline: Implications for the future of dengue control |
| Q24616798 | The dengue viruses |
| Q27473404 | The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens |
| Q40265821 | The effect of antibody-dependent enhancement, cross immunity, and vector population on the dynamics of dengue fever |
| Q52345950 | The expression profile of human peripheral blood mononuclear cell miRNA is altered by antibody-dependent enhancement of infection with dengue virus serotype 3. |
| Q38180345 | The function of Fcγ receptors in dendritic cells and macrophages |
| Q37448171 | The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity |
| Q58569778 | The immune response against flaviviruses |
| Q37904027 | The pathogenesis of dengue |
| Q63248438 | The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis |
| Q38284671 | The relevance of dengue virus genotypes surveillance at country level before vaccine approval |
| Q40568715 | The seasonal pattern of dengue in endemic areas: mathematical models of mechanisms |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q33503512 | Thrombocytopenia, hepatitis and pleural effusion in a three-month-old Mexican boy |
| Q50052067 | Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model |
| Q90197061 | Time elapsed between Zika and dengue virus infections affects antibody and T cell responses |
| Q84375956 | Transient hemophagocytic activity in dengue immunopathogenesis |
| Q27477752 | Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys |
| Q38032553 | Treatment of dengue fever |
| Q38232105 | Type I and type II Fc receptors regulate innate and adaptive immunity |
| Q90135375 | Unified feature association networks through integration of transcriptomic and proteomic data |
| Q40053434 | Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys |
| Q27473161 | Use of a short fragment of the C-terminal E gene for detection and characterization of two new lineages of dengue virus 1 in India |
| Q38967313 | Use of an immunoglobulin G avidity test to discriminate between primary and secondary dengue virus infections |
| Q34600668 | Use of expansion factors to estimate the burden of dengue in Southeast Asia: a systematic analysis |
| Q36711168 | V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1 |
| Q37330748 | Vaccine-induced enhancement of viral infections. |
| Q33390772 | Variation of the nucleotide and encoded amino acid sequences of the envelope gene from eight dengue-2 viruses |
| Q39629453 | Viral entry inhibitors block dengue antibody-dependent enhancement in vitro |
| Q92538927 | Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus |
| Q40047887 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials |
| Q27477749 | Why are dengue virus serotypes so distantly related? Enhancement and limiting serotype similarity between dengue virus strains |
| Q66679277 | Zika Virus-Immune Plasmas from Symptomatic and Asymptomatic Individuals Enhance Zika Pathogenesis in Adult and Pregnant Mice |
| Q38156674 | Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. |
Search more.